Aciex Therapeutics, Inc. — Form D
Aciex Therapeutics, Inc. of Boston, MA, a company, filed a Form D exempt-offering notice with the SEC on 2014-04-24. The offering totals $3.2M, of which $1.6M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2014-04-24
- Form: D
- Accession: 0001415518-14-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $3.2M
- Amount sold: $1.6M
- Remaining: $1.6M
- Investors: 7
- Date of first sale: 2014-04-17
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-216167
Issuer
- Name: Aciex Therapeutics, Inc.
- CIK: 0001415518
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2007
- Address: 470 Atlantic Avenue, Boston, MA, 02210
- Phone: 508-439-4946
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Mark Abelson | Director | Boston, MA |
| Les Kaplan | Director | Boston, MA |
| Dayton Misfeldt | Director | Waltham, MA |
| Jake Nunn | Director | Menlo Park, CA |
| Raj Rai | Director | Boston, MA |
| Hal Werner | Director | Boston, MA |
| Thomas Cavanagh | Executive Officer | Boston, MA |
Other filings by this issuer (1)
More